Affimed N.V. (AFMD) Analysts See $-0.16 EPS; Edgewell Personal Care Company (EPC) Had 2 Analysts Last Week

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.16 EPS on August, 14.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.16 EPS. After having $0.03 EPS previously, Affimed N.V.’s analysts see -633.33% EPS growth. The stock increased 5.03% or $0.15 during the last trading session, reaching $3.13. About 1.01M shares traded or 5.03% up from the average. Affimed N.V. (NASDAQ:AFMD) has risen 49.13% since July 13, 2018 and is uptrending. It has outperformed by 44.70% the S&P500. Some Historical AFMD News: 06/04/2018 - INCYTE CORP - EDMC REVIEW OF PHASE 3 ECHO-301/KEYNOTE-252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT; 06/04/2018 - Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination With KEYTRUDA(R) (pembrolizumab) in Patients With Unresectable or Metastatic Melanoma; 18/05/2018 - FDA Warns of Decreased Survival in Keytruda, Tecentriq Trials; 09/04/2018 - STAT Plus: With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies; 16/04/2018 - Combination Of Pembrolizumab And Chemotherapy Doubles Survival In Patients With Metastatic Lung Cancer; 16/04/2018 - Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 23/05/2018 - MERCK & CO INC - KEYTRUDA HAS NOW DEMONSTRATED AN IMPROVED SURVIVAL BENEFIT IN ADVANCED NSCLC IN FIVE PHASE 3 TRIALS; 15/03/2018 - Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting; 16/04/2018 - Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy; 02/04/2018 - Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pemb

Among 5 analysts covering Edgewell Personal Care (NYSE:EPC), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Edgewell Personal Care had 8 analyst reports since February 8, 2019 according to SRatingsIntel. The rating was upgraded by Bank of America on Friday, February 8 to “Neutral”. SunTrust maintained the stock with “Hold” rating in Monday, March 4 report. The rating was upgraded by SunTrust to “Buy” on Monday, July 8. Deutsche Bank maintained the stock with “Hold” rating in Wednesday, March 20 report. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, April 16. See Edgewell Personal Care Company (NYSE:EPC) latest ratings:

08/07/2019 Broker: SunTrust Old Rating: Hold New Rating: Buy Old Target: $35.0000 New Target: $40.0000 Upgrade
11/05/2019 Broker: BidaskScore Rating: Sell Downgrade
16/04/2019 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $39 New Target: $41 Maintain
20/03/2019 Broker: Deutsche Bank Rating: Hold New Target: $44 Maintain
08/03/2019 Broker: BidaskScore Rating: Sell Downgrade
04/03/2019 Broker: SunTrust Rating: Hold New Target: $45 Maintain
14/02/2019 Broker: Citigroup Rating: Buy
08/02/2019 Broker: Bank of America Old Rating: Underperform New Rating: Neutral Upgrade

Edgewell Personal Care Company manufactures and markets personal care products in the wet shave, sun and skin care, feminine care, and infant care categories the United States and internationally. The company has market cap of $1.53 billion. The firm operates in four divisions: Wet Shave, Sun and Skin Care, Feminine Care, and All Other. It has a 19.26 P/E ratio. It offers Schick and Wilkinson Sword razor systems, including razor handles and refillable blades, and disposable shave products for men and women; and shave preparation products, such as shaving gels and creams under the Edge, Skintimate, and Shave Guard brands.

More notable recent Edgewell Personal Care Company (NYSE:EPC) news were published by: Finance.Yahoo.com which released: “Edgewell Personal Care Company (NYSE:EPC): What Does Its Beta Value Mean For Your Portfolio? - Yahoo Finance” on June 26, 2019, also Finance.Yahoo.com with their article: “Here’s What Hedge Funds Think About Edgewell Personal Care Company (EPC) - Yahoo Finance” published on June 19, 2019, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For July 8, 2019 - Benzinga” on July 08, 2019. More interesting news about Edgewell Personal Care Company (NYSE:EPC) were released by: Benzinga.com and their article: “10 Biggest Price Target Changes For Monday - Benzinga” published on July 08, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is Edgewell Personal Care Company (NYSE:EPC) A Financially Sound Company? - Yahoo Finance” with publication date: May 10, 2019.

The stock increased 0.28% or $0.08 during the last trading session, reaching $28.22. About 511,647 shares traded. Edgewell Personal Care Company (NYSE:EPC) has declined 21.91% since July 13, 2018 and is downtrending. It has underperformed by 26.34% the S&P500. Some Historical EPC News: 14/05/2018 - EDGEWELL PERSONAL CARE ANNOUNCES THE APPOINTMENT OF MARISA IASENZA AS CHIEF LEGAL OFFICER; 14/05/2018 - Hawaiian Tropic® Launches New Sun Care Products Designed To Protect And Nourish Skin During And After Sun Exposure; 01/05/2018 - Stayfree And Jenny Mollen Aren’t Holding Back On Periods And Pee; 14/05/2018 - Ajo Buys New 1.1% Position in Edgewell; 03/05/2018 - Edgewell Personal Care 2Q Net $65.1M; 06/03/2018 - EDGEWELL CUT TO Ba3 FROM Ba2 BY MOODY’S; 03/05/2018 - Edgewell Personal Care Sees FY18 Project Fuel Restructuring Charges of About $40M; 18/05/2018 - Kimberly-Clark, Johnson & Johnson’s, Procter & Gamble and Edgewell Personal Care have reported sale declines in their baby businesses this year; 03/05/2018 - Edgewell Personal Care Sees FY18 Adjusted Effective Tax Rate 22%-24%; 03/05/2018 - Edgewell Personal Care Sees FY18 Net Sales Down About 50 Basis Points, Organic Net Sales Down 3%

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $205.04 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More notable recent Affimed N.V. (NASDAQ:AFMD) news were published by: Nasdaq.com which released: “All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy - Nasdaq” on July 02, 2019, also Globenewswire.com with their article: “Affimed Added to the Russell 2000®, 3000® and Microcap Indexes - GlobeNewswire” published on July 01, 2019, Seekingalpha.com published: “Microcaps mostly among midday movers - Seeking Alpha” on June 24, 2019. More interesting news about Affimed N.V. (NASDAQ:AFMD) were released by: Fool.com and their article: “Are Natural Killer Cells the Next Big Thing in Immunotherapy? - Motley Fool” published on July 08, 2019 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs - Benzinga” with publication date: June 15, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.